As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Annual Report 2022

Year 2022 laid the foundations for a new chapter in Genopole’s history. This new chapter is being written in coherence with the ambitions of the French Nation, as expressed in the France 2030 plan, and those of the Île-de-France Administrative Region, with its Impact 2028 plan for economic development, innovation and internationalization.
Annual Report 2022 >

A dynamic of reinvention

France needs cutting-edge laboratories and innovative start-ups to meet its goals in health security & independence, industrial relocalization, and decarbonization & the green economy transition.
The academic laboratories and biotech businesses that Genopole accompanies are busy inventing new ways to empower manufacturing, healthcare, farming, nutrition, mobility and more. Genopole itself is focused on inventing new tools and spaces to support their creativity.

Thereto, the biocluster benefits from the continuing support of the French Ministry of Higher Education and Research, as reiterated by Minister Sylvie Retailleau, whom we had the pleasure of welcoming at Genopole in November. We thank her again for her mobilization to boost the GIP during her presidency of Paris-Saclay University. The arrival of Gilles Trystram at the helm of the GIP has accelerated this dynamic.

From innovation to production

To convert this enormous research and innovation potential into production potential, Genopole has developed an ambitious real estate strategy to be deployed in 2023. It involves several construction programs under the guidance of SEM teams headed by David Bodet.

The careful consideration of feedback from Genopole’s accompanied businesses, who notably confront challenges related to premises, enabled a change of Évry-Courcouronnes’s urban land use plans (in association with Grand Paris Sud) to ease the construction of large industrial facilities, which will bring recognition to Genopole as a site for biomanufacturing in France.
The arrival of Gilles Trystram at the helm of the GIP has accelerated this dynamic.

Sparking innovation

What a good way to express how Genopole stimulates and accompanies the desire to pioneer, and how it welcomes up-and-coming talent in a composite and dynamic ecosystem where novel research topics regularly see the day.
For example, since its launch, the Atige program has made it possible for 34 researchers to create their own teams at the biocluster.
The inventiveness at Genopole is also fueled by local synergies.
To illustrate, in 2022, eight innovative projects proposed by staff members at the South Île-de-France Medical Center (CHSF) where chosen by Genopole for development in partnership with researchers at the biocluster and students at Évry-Courcouronnes’s Grandes Écoles.
The Shaker is one of Genopole’s outstanding programs. It identifies the best innovative ideas and molds them into new start-ups: year 2022 saw 12 projects developed in this way.

State-of-the-art technological platforms

To develop innovation and build sectors, Genopole invests €1 million annually into the acquisition of cutting-edge technological tools, made available thereafter to the campus’s laboratories and companies. Rigorously updated in consultation with research organisms and universities, this armada of 25 technological platforms provides world-reaching competitiveness to Genopole and contributes to its attractiveness.

Together, those aspects lead companies to choose Genopole right out of the gate: in 2022, eight new companies joined Genopole for its real estate offer and accompaniment, particularly within the growth-enabling Gene.iO program.
These companies are not abandoned in their Europe & international aims either. There also, Genopole provides support through its exploratory missions and business matchmaking via its network of investors, financers and sister hubs.

This growing international visibility reached a new mile-marker in 2022 thanks to the European Commission’s green light for the Genopole-coordinated COBIOE project aimed at supporting the development of drug biomanufacturing.

It goes without saying that the accomplishment of all these missions is built upon the unfaltering support from our members, the French State, the Île-deFrance Administrative Region, the Essonne Administrative Department, Grand Paris Sud and AFM-Téléthon, who provide 79% of Genopole’s funding. In 2023, Genopole aims to pursue its actions to enable biomanufacturing, company maturation and research in a strengthened plan of action in partnership with Paris-Saclay University.


To consult the activity report in its entirety, go to the following address:

Download the PDF >>>


Annual Report 2022 - Key Figures

With the support from
Région île de France